Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CVS Suit Against Prasco Illustrates Pricing Leverage From Caremark Merger

Executive Summary

A lawsuit by CVS Caremark against generic drug manufacturer Prasco illustrates the potential cross-market leverage that the combined pharmacy/PBM entity is able to wield

You may also be interested in...

CVS Caremark Takes Measured Approach In “Go To Market” Strategies

CVS Caremark is in the process of introducing new "cross-functional" products and services to its health plan clients, CEO Thomas Ryan said during the firm's second quarter earnings call Aug. 2

Express Scripts Tells Caremark Shareholders Vertical Mergers With PBMs Fail

A merger between pharmacy benefit manager Caremark and pharmacy chain CVS would be plagued by the same problems that vertical mergers involving PBMs have faced in the past, PBM Express Scripts argues in a pamphlet to Caremark shareholders

Orphan Drug Czar Will Push Legislators For More Grant Funding In 2008

For the past 15 years, funding for the grants program at FDA's Office of Orphan Products Development has remained stagnant at $14 million




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts